Introduction
The assembly of human immunodeficiency virus type 1 (HIV-1) particles is a complex multistep process that is presumed to be initiated by the interaction of Gag polyprotein precursors. In addition to structural Gag, Pol and Env products, HIV-1 virions were shown to contain the accessory protein Vpr. Indeed, several studies reported that Vpr could be efficiently incorporated in trans into HIV virions at molar quantities equivalent to those of Gag proteins. 1, 2 This incorporation of Vpr into progeny virions has long been thought to play an important role in the early events of viral replication before viral gene expression occurs. Studies by Heinzinger et al 3 have demonstrated that, together with p17 gag , Vpr actively mediated the nuclear transport of HIV-1 proviral DNA in nondividing target cells. More recently, a second biological activity was specifically associated with Vpr expression: growth arrest of cells at the G2 stage of the cell cycle. [4] [5] [6] [7] Interestingly, this cell-cycle modulating activity of Vpr was recently shown to optimize HIV viral expression and production in dividing T cells, as well as in macrophages. [8] [9] [10] In an attempt to understand the mechanism(s) underlying Vpr incorporation into HIV virus, some studies have shown that a predicted alpha-helical domain located near the N-terminus of Vpr plays a critical role in the virion incorporation of the protein. 11, 12 Conversely, mutagenic studies on HIV Gag revealed that Vpr virion incorporation was mediated through an interaction of Vpr with the p6 domain of the HIV Pr55 gag precursor. 13-17 A conserved LXXLF sequence in the C-terminal region of the p6 domain appears to play a critical role for Vpr incorporation into HIV virions. 18, 19 However, until now, evidence for a direct interaction between Vpr and p6 has still been missing. More recently, several studies have shown that an interaction between Vpr and the nucleocapsid protein p7 (NCp7) occurs in vitro by a recognition mechanism requiring the zinc fingers of NCp7. 20, 21 Thus, the molecular mechanism(s) involved in Vpr virion incorporation remains to be defined.
The efficient incorporation of Vpr into viral particles makes it possible to deliver heterologous proteins as Vpr fusion proteins into HIV-1 virions. Using this strategy, two recent studies reported that Vpr-mediated virion delivery of HIV reverse transcriptase (RT) or integrase (IN) can trans-complement RT-or IN-defective HIV viruses. 22, 23 In addition, this Vpr-mediated virion incorporation of heterologous proteins represents a therapeutic approach to interfere with the infectivity of HIV viruses. Indeed, several reports recently indicated that Vpr or Vpx can efficiently deliver heterologous proteins, including enzymatic or trans-dominant proteins, into HIV virions. [24] [25] [26] [27] [28] Vpr-mediated trans-incorporation of these fusion molecules into viral particles provoked a substantial inhibition of HIV replication and/or infectivity. 27, 28 More recently, Kobinger et al 28 showed the feasibility and effectiveness of this strategy using stable cell lines expressing Vpr-fusion proteins, hence demonstrating the possible application of such a strategy for HIV gene therapy.
In this study, we performed a systematic analysis of this Vpr-based virion targeting system. Several Vprchloramphenicol acetyltransferase (CAT) fusion proteins were generated to investigate: (1) the minimal Vpr amino acid sequence and its positioning within the fusion protein for efficient and specific virion incorporation; (2) the effect of HIV protease-cleavage site inserted between Vpr and CAT on the release of heterologous proteins into HIV virions; and (3) whether the presence of HIV-I protease cleavage sites in Vpr-CAT fusion proteins potentiates their effect on viral infectivity.
Results

HIV virion-incorporation of different Vpr-CAT fusion proteins
To delineate the minimal region of Vpr required for efficient virion incorporation of Vpr-fusion proteins, we constructed a series of Vpr-CAT chimeric proteins by fusing different fragments of Vpr to the N-or C-terminus of CAT (Figure 1a ), as described in Materials and methods. Several structural domains of Vpr have been shown to be involved in different activities of the protein. An Nterminal putative alpha-helical domain and a previously identified leucine/isoleucine rich region (LR-domain) in the middle region of Vpr have respectively been shown to be important for Vpr virion incorporation and nuclear localization, whereas the arginine-rich C-terminal domain was shown to be required for Vpr cell-cycle arrest activity (Figure 1a) . 11, 12, [29] [30] [31] Different Vpr segments encompassing each of these functional domains were generated to test their ability to mediate the incorporation of Vpr-CAT fusion proteins into HIV virions.
To evaluate the virion incorporation efficiency of each Vpr-CAT fusion protein, we cotransfected COS-7 cells with plasmid expressors encoding each Vpr-CAT fusion protein and an HIV-1 proviral construct (HxBRUR − ) which does not express Vpr. 12 Forty-eight hours after transfection, [ 35 S]methionine-labeled cells and pelleted virions were first immunoprecipitated with a mix of antiVpr and anti-CAT antibodies and subsequently with an HIV-1 positive human serum. Results revealed that comparable amounts of HIV-1 viral structural proteins (p24 gag ) were detected in all transfected cells and viral lysates (Figure 1b, lower panel) . In addition, wild-type Vpr, CAT and all Vpr-CAT fusion proteins, including R1-42CAT, R1-62CAT, R1-80CAT, R1-88CAT and R14-88CAT, were specifically detected in the corresponding cell lysates (Figure 1b , upper left panel, lanes 2-8). The molecular weight of the different Vpr-CAT fusion proteins ranged between approximately 29 kDa and 35 kDa. Analysis of viral lysates indicates that Vpr-CAT fusion proteins R1-42CAT, R1-80CAT, R1-88CAT and R14-88CAT are packaged into virions at various levels as compared with the wild-type Vpr (Figure 1b , upper right panel, lanes 10 and 12; 14-16). In contrast, the CAT protein and the fusion protein R1-62CAT were not detected in the virions even though they were well expressed in COS-7 cells, indicating that they do not have the ability to be incorporated into virions (Figure 1b , upper panel, lanes 11 and 13). To rule out the possibility that the protein stability may affect the levels of Vpr-CAT fusion protein virion incorporation, the expression of each Vpr-CAT protein was evaluated by pulse-chase labeling and immunoprecipitation, as described in Materials and methods. Results reveal that, similar to the wild-type Vpr, all the Vpr-CAT fusion proteins analyzed in this study were stable for up to 7 h (data not shown).
To evaluate further the incorporation efficiency of each Vpr-CAT fusion protein, levels of Vpr and Vpr-CAT detected in virions were quantified by densitometric scanning analysis of the autoradiograms presented in Figure 1b . Virion-associated Vpr or Vpr-CAT levels were calculated as a ratio of virion-associated Vpr or Vpr-CAT protein over the total amount of Vpr or Vpr-CAT fusion protein expression. This ratio was also adjusted relatively to the levels of virion-associated p24 gag protein, which was taken as an internal control. The calculated ratios reveal that R14-88CAT and R1-88CAT were incorporated into HIV as well as the wild-type Vpr, whereas R1-42CAT and R1-80CAT appeared to be less efficiently incorporated (Figure 1c) .
To demonstrate clearly that the Vpr-CAT fusion proteins were incorporated into viral particles, we purified HIV virions by sucrose gradient sedimentation technique and probed virions for the presence of fusion protein by immunoprecipitation, as described in Materials and methods. Figure 1d shows the results obtained with R14-88CAT since its virion incorporation was as efficient as the wild-type Vpr. Immunoprecipitation of the sucrose gradient fractions with a monoclonal anti-HIV p24 gag or anti-CAT antibodies reveals that peak amounts of R14-88CAT and HIV-1 p24 gag are detected in the same fractions (fractions 5-7), thus strongly indicating that R14-88CAT is packaged into HIV-1 viral particles. Similar results were obtained with R1-42CAT, R1-80CAT and R1-88CAT fusion proteins (data not shown).
The effect of Vpr position within the fusion protein on virion incorporation To test whether the position of the Vpr segment relative to CAT had an effect on the fusion protein virion incorporation, we generated constructs where the Vpr segments, R14-88 or R3-42, were fused at the C-terminus of CAT, as shown in Figure 1a . Plasmids encoding R14-88CAT, CATR14-88, R1-42CAT and CATR3-42 were each cotransfected with the Vpr − provirus plasmid HxBRUR 
(c) Quantification of virion incorporated Vpr-CAT proteins. Levels of virion-incorporated Vpr-CAT fusion proteins were calculated as a ratio of virion-associated Vpr-CAT over the total amount of Vpr-CAT protein. This ratio was also adjusted relatively to the levels of virion-associated p24 gag protein. The level of virion-associated wild-type Vpr was arbitrarily set as 100%. (d) Sucrose gradient analysis. HIV particles containing R14-88CAT fusion proteins were layered on to a 20-60% continuous sucrose gradient and ultracentrifuged. Different fractions were then analyzed for the presence of the R14-88CAT fusion protein (upper panel) and HIV
Requirement of the Pr55
gag p6 domain for Vpr-CAT fusion protein virion incorporation Several studies have demonstrated that Vpr virion incorporation requires the presence of an intact p6 domain in the HIV Gag precursor. [13] [14] [15] [16] [17] [18] [19] To test whether the incorporation of the different Vpr-CAT fusion proteins was also p6-dependent, we cotransfected COS-7 cells with the Vpr-CAT expressors and either the HxBRUR − or a p6-defective HIV-1 provirus (HxBRUR 
/p6
− provirus reflects the C-terminal deletion of p6. 32 Even though similar amounts of each Vpr-CAT fusion protein were detected in both HxBRUR whereas virion incorporation of R1-42CAT and CATR3-42 occurs even in the absence of p6.
Analysis of the processing of virion-associated Vpr-CAT fusion proteins containing HIV-1 protease cleavage sites The possibility of releasing Vpr fusion partners in their native forms into viral particles is highly desirable since some fusion partners may lose their biological activity in the context of a fusion protein. Toward this goal, we inserted the HIV protease-cleavage amino acid sequences: SQNY/PIV or ARVL/AEA between the Vpr segment R14-88 and CAT and generated the R14-88CAT-pcs2 and R14-88CAT-pcs3 expression plasmids (Figure 4a ). These amino acid sequences correspond respectively to the processing sites located between HIV p17 gag and p24 gag , and between p24 gag and p2 gag . Previous studies have shown that these amino acid sequences are efficiently cleaved by the HIV protease in vitro. 33 To determine whether the R14-88CAT-pcs fusion proteins could be nonspecifically cleaved in host cells in the absence of HIV infection, we first expressed R14-88CAT-pcs2, R14-88CAT-pcs3 or R14-88CAT proteins in COS-7 cells and performed pulse-chase labeling experiments. Detection of the Vpr fusion proteins by immunoprecipitation using rabbit anti-CAT antibodies revealed that, like R14-88CAT, both R14-88CAT-pcs2 and R14-88CAT-pcs3 were relatively stable for up to 5 h. Moreover, no cleaved
Figure 4 Specific processing of Vpr-CAT-pcs fusion proteins containing different HIV-1 protease-cleavage sites. (a) Generation of constructs encoding Vpr-CAT-pcs fusion proteins. Each of HIV protease-cleavage sites was inserted between Vpr segment R14-88 and CAT, as described in Materials and methods. The amino acid sequence and the position of each cleavage site are indicated (pcs: protease cleavage site). (b) Stability of Vpr-CAT-pcs proteins. COS-7 cells transfected with each R14-88CAT-pcs expressors, as indicated, were pulse radio-labeled for 30 min and chased for different time-points. Cell samples were then lysed and immunoprecipitated with anti-CAT antibodies. (c) Cleavage of Vpr-CAT-pcs fusion proteins by the HIV protease in the viral particles. The wild-type and protease-defective HIV viral particles containing each of Vpr-CAT or Vpr-CAT-pcs proteins were lysed, immunoprecipitated with anti-CAT antibodies (upper panel), and subsequently with an HIV-positive human serum (low panel). The positions of Vpr-CAT fusion proteins and cleaved CAT product are indicated.
CAT products were detected in the cell lysates (Figure 4b ). These results indicate that Vpr-fusion proteins containing HIV protease-cleavage sites did not undergo nonspecific proteolytic cleavage in COS-7 cells.
To test whether these Vpr-fusion proteins could be efficiently incorporated and subsequently processed in HIV-1 viral particles, each of the Vpr-CAT-pcs expressors was cotransfected in COS-7 cells with either HxBRUR − or a protease-defective provirus (SVC-p2). 34 Following radiolabeling for 16 h, viral particles were pelleted, lysed and immunoprecipitated first with anti-CAT antibodies and subsequently with the HIV-positive human serum. The SDS-PAGE analysis of immunoprecipitates reveals that the HIV protease-cleaved product p24
gag is clearly present in the wild-type virions (Figure 4c, lower panel,  lanes 1, 2 and 4) , whereas in HIV protease-defective viral particles, only uncleaved pr55 gag precursor is primarily detected (Figure 4c, lower panel, lanes 3 and 5) . In parallel, anti-CAT immunoprecipitations show that each of the three Vpr-fusion proteins is clearly detected in released viral particles (Figure 4c, upper panel, lanes 1-5) . Interestingly, in addition to the intact fusion proteins R14-88CAT-pcs2 or R14-88CAT-pcs3, large amounts of cleaved CAT products are detected in wild-type HIV viral particles (Figure 4c, upper panel, lanes 2 and 4) . However, no such cleaved CAT products were detected in protease-defective virions (Figure 4c , upper panel, lanes 3 and 5). As expected, no cleaved CAT products were detected in wild-type viral particles containing R14-88CAT proteins (Figure 4c, upper panel, lane 1) . This indicates that the presence of an HIV protease processing site in Vpr-CAT fusion proteins allows the specific cleavage of the fusion partner by the HIV protease in the viral particles.
Effect of Vpr-CAT fusion proteins on HIV-1 infectivity We next tested whether the presence of Vpr-CAT proteins might affect the infectivity of progeny virions. Vpr-CAT fusion proteins were incorporated in trans into HIV virions by cotransfection of COS-7 cells with HxBRUR − and Vpr-CAT (Figure 5a and c) or Vpr-CAT-pcs expressors (Figure 5b and d) . Viruses collected from COS-7 cells cotransfected with HxBRUR − and SVCMVVPR − , a plasmid which encodes a non-functional Vpr gene (initiation codon ATG-mutant), were used as a control. The infectivity of the progeny viruses derived from these cotransfected cultures was evaluated by MAGI assay in HeLa-CD4-␤-Gal cells 35 and in T lymphoid MT4 cells. Briefly, HeLa-CD4-␤-Gal cells or MT4 cells were infected for 2 h with equal amounts of virus as determined by virion-associated reverse transcriptase (RT) activity. After 2 to 3 days, the number of infected cells (␤-galactosidase-positive cells) in each infected HeLa-CD4-␤-Gal cell culture or the HIV-specific RT activity from infected MT4 cell cultures were determined, as described in Materials and methods. Results of Figure 5a and c reveal that expression of R1-42CAT, R1-80CAT, R1-88CAT, R14-88CAT, CATR3-42 and CATR3-96 fusion proteins reduced viral infectivity to 40-70%, as compared with the wild-type virus (100%) in both HeLa-CD4-␤-Gal cells or MT4 cells. Interestingly, the R1-62CAT fusion protein, that lost the ability to be incorporated into virions, did not affect viral infectivity (Figure 5a and c) . These results indicate that the incorporation of Vpr-CAT fusion proteins into HIV virus impairs viral infectivity albeit to different degrees.
We also compared the infectivity of viruses containing either R14-88CAT or R14-88CAT-pcs fusion proteins using the same infection systems. Interestingly, the presence of R14-88CAT-pcs2 or R14-88CAT-pcs3 in the virions resulted in a drastic decrease of viral infectivity (25-40%), as compared with the wild-type viruses (100%) or with viruses containing the corresponding fusion protein (R14-88CAT) without a protease cleavage site (70%) in both HeLa-CD4-␤-Gal cells and T lymphoid MT4 cells (Figure 5b and d) . These results clearly indicate that the insertion of HIV protease-cleavage sites in Vpr-CAT fusion proteins achieves an additional inhibitory effect on HIV infectivity.
To test whether this more potent inhibition of viral infectivity by Vpr-CAT-pcs fusion proteins may be due to an interference of HIV Gag precursor processing, we cotransfected COS-7 cells with HxBRUR − and each of the R14-88CAT, R14-88CAT-pcs2 or R14-88CAT-pcs3 expressors. Following a pulse-labeling with [ 35 S]-methionine for 20 min and chase for different time-points, equal amounts of cells were lysed, immunoprecipitated with the human anti-HIV serum and analyzed by electrophoresis. To determine the processing rate of HIV Gag precursor in each cotransfected cell culture, the levels of p24 gag product and Pr55 gag precursor at each time-point were evaluated by densitometric analysis of the auto-
Figure 5 Effect of Vpr-CAT fusion proteins on viral infectivity. HeLa-CD4-␤-Gal cells or T lymphoid MT4 cells were infected with equal amounts of viruses (as determined by RT measurement) derived from COS-7 cells cotransfected with HxBRUR − and either different Vpr-CAT (a and c) or Vpr-CAT-pcs expressors (b and d). The wild-type viruses were derived from COS-7 cells cotransfected with HxBRUR
− and SVCMVVPR
− . At 2 days after infection, the number of infected HeLa-CD4-␤-Gal cells (␤-Gal-positive cells) was determined in duplicate using the MAGI assay 35 and shown in panels a and b. The infectivity (% infectivity) of each virus stock was calculated as the ratio of the number of ␤-Gal-positive cells relative to the number of ␤-Gal-positive cells obtained with the wild-type virus (HxBRUR − ). This number of ␤-Galpositive cells ranged between 175 and 200 positive cells and was set at 100%. Viral replication in the infected T lymphoid MT4 cell culture was monitored at 3 days after infection by measuring HIV RT activity in the supernatant (panels c and d). Means (± standard errors) from three independent experiments are presented.
radiograms. As a control, the levels of HIV gp120 glycoprotein and envelope precursor gp160 were also measured. Results from Figure 6a indicate that, in the presence of R14-88CAT, the ratio of p24 gag /Pr55 gag reached, respectively, 1.6 and 2.1 at 3 and 5 h after pulse-labeling, whereas, in the presence of R14-88CAT-pcs2 or R14-88CAT-pcs3, the ratio of p24 gag /pr55 gag was only approximately 1 and 1.3, respectively (Figure 6a ). In contrast, no difference in the HIV envelope glycoproteins was observed (Figure 6b ). These results suggest that the presence of the protease-cleavage site in Vpr-CAT-pcs fusion proteins interferes specifically with the processing of HIV Gag precursor and consequently affects the infectivity of virions.
Discussion
In this study, we systematically investigated the use of Vpr as a signal to incorporate heterologous proteins into HIV virions. Using the CAT protein as a fusion partner, we first carried out a deletion analysis of Vpr to determine the minimal domain necessary for virion incorporation. Our results indicate that a Vpr segment, encompassing amino acids 14 to 88, which contains the N-terminal helical domain and the LR domain optimally delivers Vpr fusion proteins into HIV virions, while having no cell cycle arrest activity (data not shown). Fusion of Vpr at the N-or C-terminus of CAT equally targeted fusion proteins into viral particles. Insertion of HIV protease-cleavage sites between Vpr and CAT can efficiently deliver and subsequently release the CAT protein into HIV particles. Moreover, our results indicate that virion incorporation of Vpr-CAT fusion proteins impairs the infectivity of progeny viruses. Interestingly, this antiviral effect was potentiated by the presence of HIV protease cleavage sites within the Vpr-CAT fusion proteins.
Several functional domains in HIV-1 Vpr have been identified and shown to be involved in different activities of the protein. 1, [3] [4] [5] [6] [7] 36 Among them, the N-terminal putative alpha-helical domain was shown to play a critical role in Vpr's ability to be incorporated into HIV virions. 11, 12, 31 Surprisingly, our deletion analysis indicates that the LR domain of Vpr is also required for efficient virion incorporation of Vpr-CAT fusion proteins. The removal of a stretch of amino acids containing the LR domain (amino acids 63 to 80) abolishes the virion incorporation capacity of the fusion protein, as shown for R1-62CAT (Figure 1b) . Sato et al 24 also obtained similar results when a Vpr segment containing the first 63 amino acids of Vpr was fused 3′ to CAT. This is obviously not due to the protein instability since the R1-62CAT fusion protein was shown to be stable (Figure 1b) . The involvement of the LR domain in Vpr virion incorporation is still not clear. Several studies, including ours, that used substitution mutagenic analysis, did not implicate this region in Vpr virion-targeting function. 11, 12, 31 These apparently conflicting results are likely due to the different type of experimental approaches used. In one case, substitution mutagenic analysis was performed on the native Vpr protein, whereas this study used a deletion analysis in the context of a Vpr-CAT fusion protein. In addition, our study reveals that, while the virion incorporation of R1-80CAT, R1-88CAT, R14-88CAT and CATR3-96, which contain the LR domain, is efficient and p6-dependent, both R1-42CAT and CATR3-42 fusion proteins, which contain only the N-terminal alpha-helical region of Vpr, are incorporated into virions through a p6-independent process. These results provide evidence indicating that the middle region of Vpr encompassing amino acids 43 to 80, including the LR domain, may be necessary for efficient and p6-dependent virion incorporation. Indeed, the presence of the LR domain may be necessary for the maintenance and correct exposure of the N-terminal helical domain for an interaction with the Gag polyprotein precursor.
The fusion of Vpr at either the N-or the C-terminus of a heterologous protein could differentially affect the biological activity of the heterologous protein. Therefore, we investigated the effect of positioning of Vpr at the Nor C-terminus of the fusion partner on virion incorporation. Results indicate that the position of Vpr segment R14-88 at the N-or C-terminus of the CAT protein equally targeted the fusion protein into HIV virions. Moreover, our results indicate that the expression of either R14-88CAT or CATR14-88 fusion protein does not affect cell growth (data not shown). These results provide valuable information for the design of Vpr fusion proteins containing fusion partners that are still biologically active.
One important issue of the Vpr-mediated virion incorporation system is the possibility of releasing heterologous proteins, such as enzymatic or toxic molecules, from the Vpr fusion proteins after incorporation into virions. Moreover, in some instances, such fusion proteins should be kept in an inactive form when expressed in cells. To achieve these goals, we specifically inserted HIV protease-cleavage sites into Vpr-CAT fusion proteins. These fusion proteins were shown to be resistant to cellular proteases and remained as intact fusion proteins in host cells. However, in the HIV-transfected cells, these Vpr-CAT fusion proteins were efficiently incorporated and cleaved by the HIV protease during viral morphogenesis (Figure 4) . Thus, this strategy provides a specific and efficient way to deliver enzymatic or toxic molecules into HIV viral particles since the cleavage of fusion proteins depends upon the activation of the HIV protease which occurs late in the viral morphogenesis process. Interestingly, two recent reports demonstrated that reverse transcriptase (RT)-or integrase (IN)-defective HIV viruses could be rescued in trans by exogenous Vpr-RT or Vpr-IN fusion proteins, which contained natural HIV protease cleavage sites between the Vpr and the enzymatic segments. 22, 23 Previous studies have shown that virion incorporation of Vpr fusion proteins such as Vpr-HIV protease mutant, Vpr-polypeptide derived from the C-terminus of HIV-1 Vpu, Vpr-CAT and Vpr-staphylococcal nuclease impaired HIV infectivity. [26] [27] [28] In this study, using different Vpr-CAT fusion proteins, we clearly correlated the suppressive effect on viral infectivity with the virion incorporation ability of the fusion proteins. Indeed, the R1-62CAT fusion protein that lost the ability to be incorporated into virions had no effect on viral infectivity. Interestingly, contrasting results have been obtained by other laboratories regarding the effect of virion-associated VpxCAT fusion proteins on viral infectivity. 25, 27 The differential antiviral effects displayed by VprCAT and VpxCAT is likely the result of differences in the overall structure of these fusion proteins (VprCAT versus VpxCAT) or is due to their distinct localization within the virion.
A recent study by Serio et al 37 demonstrated that the insertion of HIV protease-cleavage sites in the Vpr gene, in the context of proviral constructs, impaired the infectivity of HIV viruses. In this study, we confirm and extend these results by showing that the insertion of an HIV protease-cleavage site in Vpr-CAT fusion protein (termed as Vpr-CAT-pcs) not only releases cleaved CAT molecules into HIV viral particles, but also potentiates the antiviral effect mediated by the fusion proteins (Figure 5b and d) . Since, in our study, the Vpr-CAT-pcs fusion protein was supplied in trans, the inhibitory effect on viral infectivity could not result from a possible cisacting negative effect. Earlier biochemical analyses have shown that the HIV-1 and HIV-2 particles contain approximately 2500 Gag molecules. 38 Since Vpr and Vpx proteins are present in viral particles in molar amounts equivalent to Gag protein, 1, 2, 39, 40 it is likely that the presence of a large number of pseudo-substrates, such as R14-88CAT-pcs2 or R14-88CAT-pcs3, in viral particles may saturate the viral protease and consequently interfere with the processing of viral precursor protein leading to maturation defects. Indeed, our pulse-chase data reveal that the presence of R14-88CAT-pcs2 and R14-88CAT-pcs3 inhibits the processing of HIV Gag precursors during viral assembly ( Figure 6 ).
Overall, this study presents a systematic analysis of a Vpr-based delivery system for targeting foreign proteins into HIV-1 viral particles. Our data provide a model system for the development of Vpr fusion proteins that could be used: (1) as gene therapeutic agents to combat HIV infection in vivo; and (2) as research reagents to understand HIV enzyme function independent of the Gag-Pol precursor as well as the basic process of retroviral assembly and maturation.
Materials and methods
Cell lines, antibodies and HIV-1 proviruses COS-7, an African green monkey kidney cell line, and human embryonic kidney 293T cells were propagated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS). MT4 cells, a HTLV-1 transformed T lymphoid cell, were propagated in RPMI-1640 medium supplemented with 10% FCS.
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The HeLa-CD4-␤-Gal cell line was obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, Bethesda, MD, USA. The purified rabbit anti-CAT antibodies were purchased from 5′Prime-3′Prime, (Boulder, CO, USA). The HIV-1-positive human serum 162 and the rabbit anti-Vpr serum have been pre- − (S17/s), in which the codon specifying for serine residue 17 in the p6 domain of HIV Gag was changed to a stop codon TGA, as described previously. 32 The protease-defective HIV provirus SVC-p2 was a gift from Dr Gö ttlinger. 34 The wild-type Vpr expressor SVCMVVPR + and the negative control plasmid SVCMVVPR − that encodes a non-functional Vpr gene (initiation codon ATG-mutant), were previously described. 12 Construction of Vpr-CAT expression plasmids Most of the Vpr-CAT expression plasmids were derived from an intermediate plasmid SVCMVCAT-ATG − , that was constructed by inserting a PCR-amplified CAT cDNA with a mutated ATG codon and flanking XbaI and SacI sites (at 5′ and 3′ end of cDNA) into a eukaryotic expression vector SVCMVexpa containing a cytomegalovirus (CMV) immediate-early gene promoter. 12 The primers used for amplification of the CAT cDNA are as follows: 5′oligo: 5′-AAG GAA GCT TCT AGA GAG AAA AAA A-3′; and 3′oligo: 5′-TTA AAA AAA CTA GTG AGC TCC CTG CCA CT-3′. To construct Vpr-CAT fusion protein expressors, different fragments of the Vpr gene were amplified by PCR using a 5′-primer located before the initiation codon (ATG) of Vpr and 3′-primers that ended at amino acid (aa) position 42, 62, 80 or 88, respectively, in the Vpr gene. XbaI sites flanking each side of the PCR-amplified Vpr fragment were introduced. The 5'oligo is 5′-ACTTCTAGAGGATAGATGGAACAAGCC-3′. The different 3′oligos used are as follows: R1-42, 5′-ATA-GATATGTCTAGATAAGCCATGG-3′; R1-62, 5′-CAGA ATTCTAGATATGGCTTCC-3′; R1-80, 5′-GCCTATTC TAGAATGTCGACAC-3′; R1-88, 5′-GGCTCCATTTCTA-GATCTCCTCTG-3′. After digestion with XbaI, each of these Vpr fragments was inserted into the XbaI site of SVCMVCAT-ATG − in frame with the CAT gene. The plasmid R14-88CAT was generated in a similar way by inserting a PCR-amplified cDNA encoding Vpr amino acid sequence from aa residue 14 to aa residue 88 into SVCMVCAT-ATG − . In this R14-88 cDNA, 13 aa from the N-terminus of Vpr were removed and an initiation codon (ATG) preceded by an XbaI site was created at aa position 13 (5′oligo is 5′-ACTTCTAGAGGATAGATGCCACA-CAATGAA-3′). A similar construction strategy was also used to construct R14-88CAT-pcs2 and R14-88CAT-pcs3 expressors, in which each of the sequences encoding different HIV protease-cleavage sites was inserted between the Vpr and the CAT genes by PCR using 3′oligos (3′oligo for SQNY/PIV, 5′-ATCTAGATACGATCGGATAATT CTGGCTTACTCTCCTCTG-3′; 3′oligo for ARVL/AEA, 5′-ATAGAAGCCTCTGCGAGTACTCTAGCTCTCCTCT GT-3′). In addition, three other plasmid expressors, CATR3-42, CATR14-88 and CATR3-96, were generated by inserting each PCR-amplified Vpr cDNA (R3-42, R14-88 or R3-96) in frame at a newly created SacI site located at the 3′ end of the CAT gene. The introduction of this SacI site removed the last two amino acid codons (GGG GCG) of CAT, in the plasmid SVCMVCAT-ATG + .
Transfection and HIV infection
To test the virion incorporation of Vpr and Vpr-CAT fusion proteins, COS-7 cells (1 × 10 6 ) were cotransfected with 10 g of different HIV-1 proviral constructs and 20 g of the different Vpr-CAT expressors using a standard calcium-phosphate method. The transfected cells were then washed, maintained in DMEM containing 10% FCS for 48 to 72 h and used for different experiments.
For viral infectivity determination, supernatants were collected from COS-7 cells 72 h after transfection and filtrated through 0.45 m membrane filters. The titer of virions in supernatants was determined by measurement of reverse transcriptase (RT) activity. 41 The effect of virion-incorporated Vpr fusion proteins on viral infectivity was evaluated using the MAGI assay and the MT4 T cell infection assay. For the MAGI assay, HeLa-CD4-␤-Gal cells were infected with equal amounts of virus (300 000 c.p.m. of RT activity), for 2 h. After 48 h of culture, cells were fixed and the number of HIV-infected cells (␤-Gal-positive cells) was determined, as previously described. 35 To test the infectivity of HIV viruses containing different VprCAT fusion proteins in MT4 cells, equal amounts of virus (100 000 c.p.m. of RT activity) were incubated with 1 × 10 6 MT4 cells for 2 h. After being washed, MT4 cells were cultured for 72 h and supernatants were then collected for viral RT activity measurement.
Cell labeling and radioimmunoprecipitation
Forty-eight to 62 h after-transfection, COS-7 cells were labeled with 200 Ci/ml of [ SLabel; ICN, Irvine, CA, USA) for 12 h. After labeling, supernatants were first filtered through a 0.45 m membrane filter and virions in supernatants were pelleted through a 20% sucrose cushion by ultracentrifugation with a 60Ti rotor (Beckman, Ontario, Canada) at 72 714 g for 2 h. Total amounts of cells and pelleted viruses were lysed in RIPA buffer and immunoprecipitated with rabbit anti-CAT antibodies and/or rabbit anti-Vpr serum or the human HIV-1-positive serum as described previously. 12 Immunoprecipitates were then run on a SDS-12.5% polyacrylamide gel and subsequently analyzed by autoradiography.
For pulse-chase labeling, transfected COS-7 cells were first starved 48 h after transfection in methionine-free DMEM medium for 15 min and scraped off the Petri dish during the starvation. Cells were then pulse-labeled with 300 Ci of [ 35 S]methionine in 0.5 ml of medium for 20-30 min and washed with complete DMEM containing 10% FCS. Following several washes, labeled cells were resuspended in 2-3 ml of complete DMEM containing 10% FCS and incubated at 37°C. At different time-points, equal amounts of cells were collected, lysed and immunoprecipitated with different antibodies, as described previously. 12 Densitometric analysis of autoradiograms was performed with a Molecular Dynamics Personal densitometer (Molecular Dynamics, CA, USA) using an ImageQuantTM software version 3.22.
Sucrose gradient ultracentrifugation
The virions in supernatants were first pelleted through a 20% sucrose cushion by ultracentrifugation at 72 714 g as described above and resuspended in TNE buffer (10 mm Tris, pH 7.5, 100 mm NaCl, 1 mm EDTA). Virion preparations were then sedimented through a linear 20% to 60% sucrose gradient by ultracentrifugation at 129 540 g for 16 h with a Beckman SW41Ti rotor. After ultracentrifugation, different fractions were collected and analyzed by immunoprecipitation with the monoclonal anti-HIV p24 gag or the anti-CAT antibodies, as described previously. 26 
